Spero Therapeutics, Inc.

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. The company's primary pipeline includes Tebipenem HBr, an oral carbapenem-class antibiotic currently in Phase 3 development for complicated urinary tract infections and pyelonephritis in adult patients, and SPR720, a novel candidate for first-line treatment of nontuberculous mycobacterial pulmonary disease. The company operates through licensing partnerships with established pharmaceutical entities, including agreements with Meiji Seika Pharma Co., Ltd. for tebipenem HBr development, Everest Medicines for regional commercialization rights in Greater China and Southeast Asia, and Vertex Pharmaceuticals for patent rights related to oral prodrug candidates.

As a clinical-stage entity, Spero does not currently generate commercial revenue from approved products. The company operates with a lean organizational structure of 32 full-time employees and is headquartered in Cambridge, Massachusetts. Its geographic reach extends through its partnership network, which includes development and commercialization rights across North America and Asia-Pacific regions. The company is incorporated in Delaware and trades on Nasdaq.